Market Overview

UPDATE: D.A. Davidson & Co. Reiterates On Commercial Metals As Americas Mills Shines, Other Operations Are Mixed

Share:

In a report published Monday, D.A. Davidson & Co. analyst Brent Thielman reiterated a Buy rating on Commercial Metals Company (NYSE: CMC), but lowered the price target from $25.00 to $23.00.

In the report, D.A. Davidson & Co. noted, “CMC posted solid results for its Americas Mills segment, with unit margins of $101 per ton and 15% year-over-year volume growth. As anticipated, volumes were higher on a sequential basis reflecting seasonal construction growth; these favorable trends appear to be continuing into Summer. We view the results as notable considering the relatively low levels of construction activity, somewhat dispersed demand regionally, and heavy import levels.”

Commercial Metals closed on Friday at $17.35.

Latest Ratings for CMC

DateFirmActionFromTo
Sep 2019DowngradesBuyNeutral
Jul 2019DowngradesBuyHold
Jan 2019UpgradesNeutralBuy

View More Analyst Ratings for CMC
View the Latest Analyst Ratings

Posted-In: Brent Thielman D.A. Davidson & Co.Analyst Color Price Target Analyst Ratings

 

Related Articles (CMC)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
WEEDCantor FitzgeraldMaintains18.9
TGTXCantor FitzgeraldMaintains19.0
SPLKCleveland ResearchDowngrades
IQVWolfe ResearchUpgrades
PRAHWolfe ResearchUpgrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

UPDATE: Bank Of America Reiterates On Hess As Execution Sustains Recovery In 2H14

pSivida Corp. Reports Positive Regulatory Outcome For ILUVIEN; Moves To National Phase For Marketing Authorizations In 10 More EU Countries